Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company based in Toronto, Ontario, Canada, with a wholly-owned subsidiary in Houston, Texas. The company's core business revolves around the development and commercialization of novel, highly selective versions of Interleukin-2 (IL-2), IL-4, and IL-13 Superkines and first-in-class Empowered Superkines. Utilizing directed evolution and AI-driven rational design, Medicenna re-engineers natural interleukins to precisely modulate immune responses, aiming to deliver first- and best-in-class treatment options for cancer and other serious immune-driven diseases, including autoimmune and inflammatory disorders.

The company's pipeline is built upon its proprietary Superkine™, BiSKIT™, and T-MASK™ platforms. Key product candidates include MDNA11, a long-acting IL-2 super-agonist currently in a Phase 1/2 ABILITY-1 study for various solid tumors. Bizaxofusp (MDNA55), an IL-4 Superkine therapy for high-grade glioma, including recurrent glioblastoma (rGBM), is Phase 3-ready and holds Fast Track and Orphan Drug status from the FDA/EMA, with Medicenna actively seeking strategic partners for its advancement. Other candidates include MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKIT™ for solid tumors, and MDNA209 and MDNA413, which are super antagonists targeting autoimmune and inflammatory diseases, respectively.

Dr. Fahar Merchant serves as the President, CEO, and Chairman of the Board, a position he has held since October 2011. In April 2026, Dr. Nageatte Ibrahim was appointed Chief Medical Officer, bringing extensive oncology and clinical development expertise to the team. Recent notable activities include the presentation of positive data for MDNA113 at AACR 2026 and an upcoming presentation on the NEO-CYT Trial (MDNA11 in melanoma) at ASCO 2026. Medicenna's 2026 outlook emphasizes maximizing MDNA11's potential, advancing MDNA113, and securing partnerships for bizaxofusp, underscoring its commitment to progressing its clinical-stage immunotherapy programs.